Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
June 6th, 2008
In a study presented today at the 39th Annual Digestive Disease Week (DDW) meeting in San Diego, California, 70 percent of patients with moderately active ulcerative colitis (UC) receiving an investigational 800 mg mesalamine tablet dosed at 4.8 g/day under development by Procter & Gamble Pharmaceuticals experienced overall improvement in disease measures. In the study, the investigational tablet and dose were compared to 400 mg mesalamine tablets dosed at 2.4 g/day. Additionally, patients in the study with a clinical history of more difficult-to-treat disease, such as those who have been previously treated with steroids and/or rectal therapies, received benefit from...
Source: Health Business Week (2008-06-06)
|
